塞力医疗: 信息披露暂缓与豁免管理制度（2025年8月）

Core Viewpoint - The document outlines the information disclosure deferral and exemption management system for Celis Medical Technology Group Co., Ltd, aiming to ensure compliance with legal obligations and protect investors' rights [1][2]. Group 1: Information Disclosure Management - The company and other obligated parties must disclose information truthfully, accurately, completely, timely, and fairly, without abusing deferral or exemption to mislead investors [1][2]. - The scope of deferral and exemption should generally align with the conditions at the time of the company's initial public offering, requiring substantial evidence for any additions post-listing [2][3]. Group 2: Confidential Information - Information that involves state secrets or commercial secrets can be exempted from disclosure if it could lead to violations of confidentiality regulations or cause significant harm to the company or others [2][3]. - If the reasons for deferral or exemption are no longer valid, or if the information becomes difficult to keep confidential, timely disclosure is required [3][4]. Group 3: Internal Procedures - Relevant departments must submit documentation and confidentiality agreements three days prior to any event for which deferral or exemption is requested, which will be reviewed by the securities department [4][5]. - The company must maintain a record of all deferrals and exemptions, including the reasons for such actions and the internal review process, for a minimum of ten years [5][6]. Group 4: Accountability and Compliance - The company has established a responsibility accountability mechanism for information disclosure, with penalties for those who fail to comply with the established rules or do not disclose information in a timely manner after the reasons for deferral have been resolved [5][6]. - The system will take effect upon approval by the board of directors and will be subject to interpretation by the board [6].